Immunosuppressant to begin trials
Isotechnika's investigational immunosuppressive drug IASTX247 is to begin Phase II trials in kidney transplant patients in north America. Preclinical and Phase I studies have shown it to be less toxic and more potent than current immunosuppresive drugs.